InvestorsHub Logo
Followers 30
Posts 2791
Boards Moderated 3
Alias Born 10/24/2015

Re: None

Tuesday, 12/05/2023 3:37:05 PM

Tuesday, December 05, 2023 3:37:05 PM

Post# of 4860
Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent GILD News